StockData

Addex Therapeutics vs CervoMed

ADXN and CRVO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ADXN and CRVO compare

Addex Therapeutics grew revenue faster over the last twelve months (−92.6% versus −95.7% for CervoMed).

CervoMed scores higher on the StockData Score (5 against 0 for Addex Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricADXNCRVO
Size and price
Market cap–$22.7M
Share price$3.50$1.50
Change, 1 year−58.7%−80.5%
Change, 5 years−97.5%−94.9%
Beta (5Y)1.953.41
Employees315
StockData Score
Total score05 (better)
Valuation score01 (better)
Growth score00
Performance score00
Health score04 (better)
Dividend score00
Valuation
P/S–68.5×
P/B–1.0×
Growth
Revenue growth (TTM)−92.6% (better)−95.7%
Revenue growth, 5Y average−61.6%–
EPS growth (TTM)−186%–
Profitability
Operating margin−9391% (better)−9407%
Net margin–−9161%
FCF margin−7244%–
Return on equity–−108%
Financial health
Debt / equity–0.00
Interest coverage−181.0×–
Current ratio0.76–
Altman Z-score–−5.50
Piotroski F-score–1
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.00%11.6%
Held by insiders15.5%36.9%
Insider net buying, 12 months–$3.0M
Short interest, % of float–12.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.